Abstract 466P
Background
The daycare caters to numerous cancer patients. Patient satisfaction is a surrogate estimator of the quality of healthcare. Determination of the factors responsible for this will help to improve patient care delivery.
Methods
Women with breast or ovarian malignancies undergoing chemotherapy at the medical oncology daycare unit from 1st January 2023 to 1st April 2023 were invited to complete the PSS questionnaire anonymously. The PSS tool is an abbreviated 28 item questionnaire related to administrative services, medical team members and the treating consultant. The response options comprised a 5-point Likert scale. The raw scores were linearly transformed to a 0-100 scale and patients scoring more than 60 were considered as satisfied.
Results
A total of 117 patients participated in the study. There was a high level of overall satisfaction rate (93.2%). Availability of social support and health insurance were significant determinants of patient satisfaction (p=0.0043 and p=0.0006 respectively). The median waiting time was 3 hours with a satisfaction rate of 84%. The satisfaction rate for secretarial assistance, medical staff and the treating physician were 94%, 94% and 93.2% respectively. The patients’ likelihood of returning to our daycare for and recommending it to others were 97.4% and 96.6% respectively.
Conclusions
Ensuring availability of social support, provision of health insurance and effective patient-physician communication is likely to increase patient satisfaction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract